| Hannah Hyeryeon Jeong, | |
|
1336 S 336th St, Federal Way, WA 98003-6348 | |
| (253) 833-7444 | |
| Not Available |
| Full Name | Hannah Hyeryeon Jeong |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 1336 S 336th St, Federal Way, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174168025 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | AP61315189 (Washington) | Secondary |
| 163W00000X | Registered Nurse | RN60848859 (Washington) | Primary |
| Entity Name | Valley Cities Counseling And Consultation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972668853 PECOS PAC ID: 6406842053 Enrollment ID: O20040421000498 |
News Archive
Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.
NEW research shows that bowel, oesophageal and pancreatic cancers have seen the greatest improvement in the time it takes from when a patient first visits their GP with symptoms to when they are diagnosed with the disease.
Jackson T. Wright Jr., MD, PhD, and researchers from University Hospitals Case Medical Center presented new results from the Systolic Blood Pressure Intervention Trial (SPRINT) showing that in patients at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of fatal and non-fatal major events or death compared to targeting systolic blood pressure to the usually recommended target of less than 140 mm Hg.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hannah Hyeryeon Jeong, 325 W Gowe St, Kent, WA 98032-5892 Ph: () - | Hannah Hyeryeon Jeong, 1336 S 336th St, Federal Way, WA 98003-6348 Ph: (253) 833-7444 |
News Archive
Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.
NEW research shows that bowel, oesophageal and pancreatic cancers have seen the greatest improvement in the time it takes from when a patient first visits their GP with symptoms to when they are diagnosed with the disease.
Jackson T. Wright Jr., MD, PhD, and researchers from University Hospitals Case Medical Center presented new results from the Systolic Blood Pressure Intervention Trial (SPRINT) showing that in patients at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of fatal and non-fatal major events or death compared to targeting systolic blood pressure to the usually recommended target of less than 140 mm Hg.
› Verified 1 days ago
Mohamed Coulibaly, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 4038 Sw 327th Pl, Federal Way, WA 98023 Phone: 253-306-9296 | |
Robert Mason, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 34122 28th Ave Sw, Federal Way, WA 98023 Phone: 253-350-3104 | |
Mercy Curtis, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 33480 13th Pl S, Federal Way, WA 98003 Phone: 253-285-7101 | |
Ms. Ashia Monique Mitchell, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 33431 13th Pl South, Federal Way, WA 98003 Phone: 253-874-7637 Fax: 253-874-7635 | |
Nawaf Alfaouri, Registered Nurse Medicare: Medicare Enrolled Practice Location: 33431 13th Pl S, Federal Way, WA 98003 Phone: 253-874-7634 Fax: 253-874-7635 | |
Hoboung Song, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 32615 10th Pl Sw, Federal Way, WA 98023 Phone: 253-517-3387 Fax: 253-517-3387 | |
Hannah Wade, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 29805 Pacific Hwy S, Federal Way, WA 98003 Phone: 253-545-3770 |